Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib in Relapsed/Refractory AML and MDS
NCT01880437Phase 2Terminated
- Sponsor
- Roche
- Start
- Sep 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of vismodegib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Roche. Started Sep 2013; status: terminated.
02
Drugs
vismodegib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01880437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01880437.